LeMaitre Vascular, Inc. (LMAT) Shares Bought by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP grew its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 4.4% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 968,232 shares of the medical instruments supplier’s stock after purchasing an additional 40,767 shares during the quarter. Dimensional Fund Advisors LP owned approximately 5.15% of LeMaitre Vascular worth $30,228,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in LMAT. Bank of New York Mellon Corp raised its holdings in LeMaitre Vascular by 1.6% during the first quarter. Bank of New York Mellon Corp now owns 88,552 shares of the medical instruments supplier’s stock worth $2,181,000 after purchasing an additional 1,408 shares in the last quarter. Prudential Financial Inc. raised its holdings in LeMaitre Vascular by 2.1% during the first quarter. Prudential Financial Inc. now owns 97,350 shares of the medical instruments supplier’s stock worth $2,398,000 after purchasing an additional 2,040 shares in the last quarter. American International Group Inc. raised its holdings in LeMaitre Vascular by 7.0% during the first quarter. American International Group Inc. now owns 8,310 shares of the medical instruments supplier’s stock worth $205,000 after purchasing an additional 545 shares in the last quarter. TIAA CREF Investment Management LLC raised its holdings in LeMaitre Vascular by 6.6% during the first quarter. TIAA CREF Investment Management LLC now owns 105,157 shares of the medical instruments supplier’s stock worth $2,590,000 after purchasing an additional 6,472 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in LeMaitre Vascular by 6.5% during the first quarter. Vanguard Group Inc. now owns 660,331 shares of the medical instruments supplier’s stock worth $16,264,000 after purchasing an additional 40,448 shares in the last quarter. 68.29% of the stock is currently owned by institutional investors.

A number of research firms have weighed in on LMAT. Canaccord Genuity reissued a “hold” rating and set a $30.00 price objective on shares of LeMaitre Vascular in a report on Monday, October 9th. Zacks Investment Research cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Thursday, September 28th. Benchmark Co. cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, October 27th. First Analysis cut shares of LeMaitre Vascular from an “overweight” rating to an “equal weight” rating and set a $34.00 target price on the stock. in a report on Friday, October 27th. Finally, BidaskClub cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Wednesday, August 23rd. Seven analysts have rated the stock with a hold rating and one has issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $32.20.

In other LeMaitre Vascular news, insider David B. Roberts sold 48,317 shares of the stock in a transaction on Friday, August 4th. The stock was sold at an average price of $33.12, for a total value of $1,600,259.04. Following the sale, the insider now directly owns 30,105 shares of the company’s stock, valued at $997,077.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Peter R. Gebauer sold 6,224 shares of the stock in a transaction on Monday, August 7th. The stock was sold at an average price of $33.85, for a total value of $210,682.40. Following the completion of the sale, the insider now directly owns 8,477 shares in the company, valued at $286,946.45. The disclosure for this sale can be found here. Over the last three months, insiders have sold 285,854 shares of company stock worth $9,851,441. Corporate insiders own 23.70% of the company’s stock.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Thursday, October 26th. The medical instruments supplier reported $0.25 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.20 by $0.05. The business had revenue of $24.80 million for the quarter, compared to analyst estimates of $25.49 million. LeMaitre Vascular had a return on equity of 16.16% and a net margin of 15.81%. The business’s revenue was up 6.9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.17 EPS.

LeMaitre Vascular announced that its Board of Directors has authorized a stock buyback program on Thursday, July 27th that authorizes the company to repurchase $7.50 million in outstanding shares. This repurchase authorization authorizes the medical instruments supplier to repurchase up to 1.4% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s board of directors believes its shares are undervalued.

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 7th. Investors of record on Wednesday, November 22nd will be given a dividend of $0.055 per share. This represents a $0.22 annualized dividend and a dividend yield of 0.69%. The ex-dividend date of this dividend is Tuesday, November 21st. LeMaitre Vascular’s dividend payout ratio is currently 28.57%.

ILLEGAL ACTIVITY NOTICE: “LeMaitre Vascular, Inc. (LMAT) Shares Bought by Dimensional Fund Advisors LP” was published by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark & copyright law. The correct version of this story can be read at https://www.com-unik.info/2017/11/02/lemaitre-vascular-inc-lmat-shares-bought-by-dimensional-fund-advisors-lp.html.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular, Inc. (NASDAQ:LMAT).

Institutional Ownership by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

What are top analysts saying about LeMaitre Vascular Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for LeMaitre Vascular Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit